Navigation Links
Wolters Kluwer Health's New Forecasting Service Models Pharma's Future
Date:6/29/2009

inThought offers market data, analysis and forecasting from a single source

BRIDGEWATER, N.J., June 29 /PRNewswire/ -- Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry, today introduced Wolters Kluwer Health inThought(TM), a new market research service that offers an array of pharmaceutical forecasting capabilities. inThought was developed to help financial analysts, health care suppliers and drug makers understand where developmental drugs, medical devices, and therapies are positioned today and where they are likely headed in the future.

inThought is among the first of a new generation of research services that can deliver data, analysis and forecasting from a single source, an approach that is both cost effective and helps streamline the market research process. inThought integrates Wolters Kluwer Health's trusted clinical, prescription, managed markets, and patient information -- recognized to be of the highest quality in the industry -- together with the keen insight and forecasting abilities developed by a team of highly skilled individuals including researchers, analysts and physicians.

"With research headcounts down, there's a fundamental shift in the way analysts and pharma customers want their research delivered," said Ben Weintraub, Director of Research, Wolters Kluwer Health inThought. "Rather than simply striving to offer more data faster, our approach sifts through the clutter to synthesize what is truly important."

Customers now have all of the tools they need from a single, independent source to aid them in making more efficient decisions about their products, markets and competitors. inThought's progressive approach benefits from the wealth of knowledge and experience provided by Wolters Kluwer Health Pharma Solutions' professional data analysts, a distinction that helps identify trends as they unfold.

"With inThought, we alleviate one of the main issues with traditional pharma research products: once you buy it, you still have to make time to use it and understand the implications for your product," said Mark Spiers, President and CEO, Wolters Kluwer Health, Pharma Solutions. "This approach provides an edge for understanding the future market for a pharmaceutical brand or medical device."

inThought research and analysis is available to customers through products such as research alerts geared toward specific customer requirements; subscriptions to a powerful, Web-based drug pipeline database that integrates inThought forecasts with detailed monitoring of drug development programs around the world; regular conference calls to connect customers with medical experts providing the physician perspective; revenue forecasts and probability of approval models for 300+ drugs in development; syndicated research reports that delve deep into specific markets; and custom research projects and counsel designed to meet individual customer needs.

For more information about Wolters Kluwer Health inThought, visit www.in-thought.com.

About Wolters Kluwer Health

Wolters Kluwer Health (Philadelphia, PA) is a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons(R); electronic information providers, such as Ovid, UpToDate(R), Medi-Span(R) and ProVation(R) Medical; and pharmaceutical information providers such as Adis International and Source(R).

Wolters Kluwer Health is a division of Wolters Kluwer, a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of euro 3.4 billion ($4.9 billion), employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Visit www.wolterskluwer.com for information about our market positions, customers, brands, and organization.

    Contact:  Tom Kivett
              Kivett & Company Communications
              (212) 727-2935
              tkivett@kivettandco.com


'/>"/>
SOURCE Wolters Kluwer Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Wolters Kluwer Health Customer Service Organization Awarded Center of Excellence Certification
2. Cogdell Spencer Names Herritz and Wolters to Key Leadership Positions Within Erdman
3. Wolters Kluwer Healths Unique Prescription Data Tapped by FDA in Effort to Advance Drug Safety
4. Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.)
5. Wolters Kluwer Health Appoints Scott Lubeck Vice President, Technology of its Professional & Education Unit
6. Wolters Kluwer Health Appoints Susan Driscoll as Executive Vice President & General Manager of the Books Business of its Professional & Education Unit
7. Wolters Kluwer Health Introduces Formulary Facts(TM), a Formulary Analytics Tool that Sets the Standard for Accuracy and Ease-of-Use
8. HealthSource of Chicago: New Techniques for Back Pain Relief in Chicago
9. iHealthSpot, Inc Named Winner in the 2009 STEVIE' AWARDS (American Business Awards)
10. HealthSouth Comments on Civil Litigation
11. Prostate Cancer Active Surveillance Protocol Clinical Trial Conducted by NorthShore University HealthSystem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: